A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
Public ClinicalTrials.gov record NCT05337137. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma
Study identification
- NCT ID
- NCT05337137
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Drug
- Nivolumab Drug
- Placebo Other
- Relatlimab Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 4, 2022
- Primary completion
- Jul 4, 2025
- Completion
- Nov 17, 2025
- Last update posted
- Jan 11, 2026
2022 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0042 | Los Angeles | California | 90033 | — |
| Local Institution - 0039 | Los Angeles | California | 90095 | — |
| Local Institution - 0034 | San Francisco | California | 94115 | — |
| Local Institution - 0030 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0059 | Baltimore | Maryland | 21231 | — |
| Local Institution - 0060 | Boston | Massachusetts | 02114 | — |
| Local Institution - 0065 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0061 | New York | New York | 10065 | — |
| Local Institution - 0062 | The Bronx | New York | 10461 | — |
| Local Institution - 0033 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05337137, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 11, 2026 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05337137 live on ClinicalTrials.gov.